1.1Polycaprolactone backing film
A compression-molded polycaprolactone film forms the face away from the tissue. The dense film limits outward transport, and the tissue-facing layer provides the lower-resistance release path.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A compression-molded polycaprolactone film forms the face away from the tissue. The dense film limits outward transport, and the tissue-facing layer provides the lower-resistance release path.
Freeze-drying an aqueous silk fibroin cast forms an interconnected pore network. Tissue fluid enters the pores, which provide a diffusion path from the adjacent mediator reservoir to the tissue.
Three strips lie side by side on a common backing with their broad faces toward the tissue. Each strip contains mediator within its polymer matrix, and its thickness and porosity control release over the area it covers.
Mediator-loaded lipid particles are dispersed through the first layer before the layer solidifies. After hydration, mediator released from the particles diffuses into the adjoining intermediate layer.
All three layers contain 75% PLGA and 25% gelatin by dry polymer mass. The dense outer face restricts transport, and interconnected pores in the tissue-facing layer provide a lower-resistance diffusion path.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Three films of poly(lactic-co-glycolic acid) (PLGA) and gelatin form a flexible strip sized for a veterinary periodontal pocket. Two dried deposits of resolvin D1 occupy the internal interfaces and sit inside a bonded perimeter. The strip sits with its gelatin-rich face against the gingiva and its PLGA-rich face toward the tooth root. Gingival crevicular fluid hydrates the films, and the gelatin-rich face provides the lower-resistance release path toward the gingiva.
Calcium-crosslinked alginate replaces gelatin as the hydrophilic phase in each of three PLGA composite films. An aqueous sodium alginate solution containing dispersed PLGA particles is cast at three solids ratios, gelled with calcium chloride, and dried. Resolvin D1 is deposited at both interfaces before the films are stacked and bonded at the perimeter. The alginate-rich face takes up water and provides hydrated diffusion paths, while the PLGA-rich face presents greater resistance to transport.
The dried laminate measures 300 µm across three PLGA and gelatin films. The PLGA-rich backing is 180 µm thick, the intermediate film is 80 µm thick, and the gelatin-rich tissue-facing film is 40 µm thick. Equal amounts of resolvin D1 per unit area occupy the two interfaces inside a bonded perimeter. The shorter path through the tissue-facing film and the longer path through the backing bias release toward the tissue-facing side.
Each internal interface of a three-film PLGA and gelatin laminate carries resolvin D1 in 0.5 mm diameter deposits on a square grid with a 1.0 mm pitch. The grid at the second interface is offset by 0.5 mm along both axes, and a 1.0 mm margin around the perimeter stays free of drug for bonding. A microdispensing head places the deposits on the backing and intermediate films before drying and lamination. The two grids form laterally staggered release sources at different depths beneath the gelatin-rich face.
A three-film PLGA and gelatin laminate forms a cuff around the exterior of a tubular vascular graft. The PLGA-rich face contacts the graft, and the gelatin-rich face contacts the surrounding tissue. Two resolvin D1 deposits occupy the internal interfaces and terminate before drug-free margins that accept fixation sutures. Fluid from the surrounding tissue hydrates the outer film, through which the mediator diffuses into the tissue around the graft.
An automated liquid dispenser applies a resolvin D1 solution of known concentration to a defined area on the backing film and on the intermediate film. A balance records each film's mass before and immediately after dispensing, and the controller calculates deposited drug mass from the mass of solution added and its drug mass fraction. If a deposit falls below the target, the controller adds a measured increment and checks the mass again. After drying, a placement stage stacks the backing, intermediate film, and gelatin-rich cover so that the two deposits occupy separate interfaces, then presses the drug-free margins together.
The second layer is an electrospun mat containing 50% PLGA and 50% gelatin by dry polymer mass. Interconnected spaces between the fibers admit tissue fluid and provide diffusion paths to the exposed face.
A 30-micrometer cast film contains 75% PLGA and 25% gelatin by dry polymer mass. The film lies between the two outer layers and separates the two mediator deposits.
Phospholipid vesicles carry resolvin D1 in two thin deposits, one at each interface of the intermediate layer. Each deposit is applied to one face of the intermediate layer before the outer layers are assembled.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Based on our previous studies on electrospinning parameters [28], PGE was electrospun into mats approximately 0.5 mm thick at 10 kV and 1.5 ml/h flow rate with 15 cm air gap distance. Resultant PGE fibers were homogenous in appearance (FIG. 1A), suggesting that the PGE fibers are hybrid fibers composed of PLGA, gelatin, and elastin, rather than a mixture of homogeneous PLGA, gelatin, and elastin fibers.A · US 8,048,446 B2 · ¶ 58
Based on our previous studies on electrospinning parameters [28], PGE was electrospun into mats approximately 0.5 mm thick at 10 kV and 1.5 ml/h flow rate with 15 cm air gap distance. Resultant PGE fibers were homogenous in appearance (FIG. 1A), suggesting that the PGE fibers are hybrid fibers composed of PLGA, gelatin, and elastin, rather than a mixture of homogeneous PLGA, gelatin, and elastin fibers.A · US 8,048,446 B2 · ¶ 58
According to some additional aspects of the present disclosure, the photo-crosslinkable material comprises gelatin methacrylate (gelMA). The method can further comprise introducing the gelMA as an interlayer into a bovine pericardium (dECM)+poly(propylene fumarate) (PPF) biohybrid vascular graft.B · US 2023/0082358 A1 · ¶ 26
The heparin-loaded gelMA layer that sits between the dECM and PPF slowly doses the pericardium with heparin, which diffuses through the dECM to provide sustained release at the surface of the graft.B · US 2023/0082358 A1 · ¶ 13
More particularly, an innovative interlayer drug delivery system within the dECM+PPF biohybrid vascular graft temporally and spatially modulates the release of heparin through an intermediate gelMA layer. By incorporating 3D printed masks of varying designs, one can spatially control the degree of gelMA crosslinking and consequently facilitate extended heparin release profiles through the biohybrid.B · US 2023/0082358 A1 · ¶ 13
An empty cell means only that no passage was reproduced there.
Problems with currently available scaffolds include the following: current scaffold need to be crosslinked, mechanical properties are not suitable for multiple applications, and limited cell in-growth.A · US 8,048,446 B2 · ¶ 9
These particular blends provide a unique mix of mechanical and physical properties that facilitates cell penetration and proliferation within the scaffolds without crosslinking.A · US 8,048,446 B2 · ¶ 12
A major obstacle in the implementation and development of small diameter vascular grafts is the prevention of thrombosis in order to maintain lumen patency.B · US 2023/0082358 A1 · ¶ 5
Alternatively, gelatin methacrylate (gelMA) has been employed to achieve long-term sustained drug release without solvents and its properties can be influenced through UV crosslinking without any impairment to cell viability.B · US 2023/0082358 A1 · ¶ 7
patent.fyi, US 2026/0355393 A1, claim 1, first published 2026-11-19T10:59:45-05:00, https://patent.fyi/US20260355393/, SHA-256 be169d11db97257380475d52e1bf7857200304836e7e55968e2d815b42abe708